- Home
- CRT vs VSTM Comparison
CRT vs VSTM Comparison
Compare CRT & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$6.51
Company Overview
Basic Information| Metric | CRT | VSTM |
|---|---|---|
| Founded | 1991 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 723.8M |
| IPO Year | 1992 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CRT | VSTM |
|---|---|---|
| Price | $8.73 | $6.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $13.38 |
| AVG Volume (30 Days) | 30.4K | ★ 2.0M |
| Earning Date | 03-12-2026 | 11-04-2025 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | $5,621,913.00 | ★ $13,379,000.00 |
| Revenue This Year | N/A | $208.54 |
| Revenue Next Year | N/A | $251.40 |
| P/E Ratio | $11.71 | ★ N/A |
| Revenue Growth | N/A | ★ 33.79 |
| 52 Week Low | $7.07 | $4.01 |
| 52 Week High | $13.31 | $11.25 |
Technical Indicators
Market Signals| Indicator | CRT | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 62.65 | 37.95 |
| Support Level | $8.26 | $6.14 |
| Resistance Level | $8.86 | $6.78 |
| Average True Range (ATR) | 0.23 | 0.59 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 78.80 | 12.04 |
Price Performance
Historical Comparison CRT
VSTM
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.